Safety Monitoring of mRNA Vaccines Administered During the Initial 6 Months of the U.S. COVID-19 Vaccination Program: Reports to Vaccine Adverse Events Reporting System (VAERS) and v-safe
Hannah G. Rosenblum(National Center for Immunization and Respiratory Diseases), David K. Shay(National Center for Emerging and Zoonotic Infectious Diseases), Paige Marquez(Centers for Disease Control and Prevention), Lauri E. Markowitz(Centers for Disease Control and Prevention), Tom T. Shimabukuro(Centers for Disease Control and Prevention), Michael M. McNeil(Centers for Disease Control and Prevention), Ruiling Liu(Nanjing Agricultural University), Tanya R. Myers(Centers for Disease Control and Prevention), Anne M. Hause(Centers for Disease Control and Prevention), Penelope Strid(Centers for Disease Control and Prevention), Winston E. Abara(Centers for Disease Control and Prevention), Bethany Baer(United States Food and Drug Administration), Bicheng Zhang(Centers for Disease Control and Prevention), John R. Su(National Center for Emerging and Zoonotic Infectious Diseases), Julianne Gee, David Menschik(United States Food and Drug Administration)
Cited by 1
Related Papers
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
|PsycEXTRA Dataset|2007|1.9k
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
|The Lancet|2019|1.3k